Sunil Pancholi

2.9k total citations · 1 hit paper
41 papers, 1.8k citations indexed

About

Sunil Pancholi is a scholar working on Genetics, Oncology and Molecular Biology. According to data from OpenAlex, Sunil Pancholi has authored 41 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Genetics, 20 papers in Oncology and 16 papers in Molecular Biology. Recurrent topics in Sunil Pancholi's work include Estrogen and related hormone effects (25 papers), Advanced Breast Cancer Therapies (15 papers) and PI3K/AKT/mTOR signaling in cancer (10 papers). Sunil Pancholi is often cited by papers focused on Estrogen and related hormone effects (25 papers), Advanced Breast Cancer Therapies (15 papers) and PI3K/AKT/mTOR signaling in cancer (10 papers). Sunil Pancholi collaborates with scholars based in United Kingdom, United States and Denmark. Sunil Pancholi's co-authors include Mitch Dowsett, Lesley‐Ann Martin, Stephen Johnston, Suzanne Drury, Ricardo Ribas, David Foreman, Simone Detre, Qiong Gao, Christopher J. Lord and Martín A. Rivas and has published in prestigious journals such as PLoS ONE, Cancer Research and Oncogene.

In The Last Decade

Sunil Pancholi

41 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

2016 511 citations María Teresa Herrera-Abreu, Marta Palafox et al. Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sunil Pancholi United Kingdom	20	947	738	714	417	398	41	1.8k
Erik Teugels Belgium	26	693 0.7×	1.2k 1.6×	561 0.8×	560 1.3×	427 1.1×	72	2.0k
Teresa Klinowska United Kingdom	22	717 0.8×	1.3k 1.7×	419 0.6×	252 0.6×	216 0.5×	62	2.0k
Martín A. Rivas Argentina	17	845 0.9×	761 1.0×	477 0.7×	397 1.0×	136 0.3×	27	1.6k
Ondrej Kalous United States	14	1.2k 1.2×	731 1.0×	958 1.3×	339 0.8×	87 0.2×	24	1.8k
Janni Mirosevich United States	12	342 0.4×	866 1.2×	626 0.9×	236 0.6×	220 0.6×	18	1.4k
Elena Levantini United States	22	785 0.8×	1.6k 2.2×	339 0.5×	536 1.3×	118 0.3×	48	3.0k
Steven Gendreau United States	15	424 0.4×	559 0.8×	494 0.7×	358 0.9×	132 0.3×	26	1.1k
Maria Sundvall Finland	20	949 1.0×	1.2k 1.6×	303 0.4×	289 0.7×	149 0.4×	33	1.8k
Mitchell Cheung United States	21	720 0.8×	1.5k 2.1×	987 1.4×	404 1.0×	116 0.3×	28	2.7k
Frédérique Spyratos France	24	660 0.7×	878 1.2×	204 0.3×	788 1.9×	280 0.7×	41	1.7k

Countries citing papers authored by Sunil Pancholi

Since Specialization

Citations

This map shows the geographic impact of Sunil Pancholi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sunil Pancholi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sunil Pancholi more than expected).

Fields of papers citing papers by Sunil Pancholi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sunil Pancholi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sunil Pancholi. The network helps show where Sunil Pancholi may publish in the future.

Co-authorship network of co-authors of Sunil Pancholi

This figure shows the co-authorship network connecting the top 25 collaborators of Sunil Pancholi. A scholar is included among the top collaborators of Sunil Pancholi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sunil Pancholi. Sunil Pancholi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Iravani, Marjan, Rania El Botty, John Alexander, et al.. (2023). Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers. Cancer Research. 84(1). 17–25. 6 indexed citations

Pancholi, Sunil, Nikiana Simigdala, Ricardo Ribas, et al.. (2022). Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer. npj Breast Cancer. 8(1). 125–125. 10 indexed citations

Pancholi, Sunil, Ricardo Ribas, Nikiana Simigdala, et al.. (2020). Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities. Oncogene. 39(25). 4781–4797. 63 indexed citations

Pancholi, Sunil, Mariana Ferreira Leal, Ricardo Ribas, et al.. (2019). Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer. Breast Cancer Research. 21(1). 135–135. 12 indexed citations

Ribas, Ricardo, Sunil Pancholi, Aradhana Rani, et al.. (2018). Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer. Breast Cancer Research. 20(1). 44–44. 16 indexed citations

Simigdala, Nikiana, Sunil Pancholi, Ricardo Ribas, et al.. (2018). Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease. British Journal of Cancer. 119(3). 313–322. 5 indexed citations

Herrera-Abreu, María Teresa, Marta Palafox, Uzma Asghar, et al.. (2016). Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer. Cancer Research. 76(8). 2301–2313. 511 indexed citations breakdown →

Guest, Stephanie K., Ricardo Ribas, Sunil Pancholi, et al.. (2016). Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation. PLoS ONE. 11(6). e0157397–e0157397. 19 indexed citations

Ribas, Ricardo, Sunil Pancholi, Stephanie K. Guest, et al.. (2015). AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo. Molecular Cancer Therapeutics. 14(9). 2035–2048. 49 indexed citations

10.

Morandi, Andrea, Lesley‐Ann Martin, Qiong Gao, et al.. (2013). GDNF–RET Signaling in ER-Positive Breast Cancers Is a Key Determinant of Response and Resistance to Aromatase Inhibitors. Cancer Research. 73(12). 3783–3795. 83 indexed citations

11.

Weigel, Marion T., Zara Ghazoui, Anita K. Dunbier, et al.. (2012). Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer. Breast Cancer Research. 14(3). R78–R78. 38 indexed citations

12.

Pancholi, Sunil, et al.. (2011). PD01-03: Src Is a Potential Therapeutic Target in Endocrine Resistant Breast Cancer Exhibiting Low Estrogen Receptor (ER)-Mediated Transactivation.. Cancer Research. 71(24_Supplement). PD01–3. 1 indexed citations

13.

Dunbier, Anita K., H Anderson, Zara Ghazoui, et al.. (2011). ESR1 Is Co-Expressed with Closely Adjacent Uncharacterised Genes Spanning a Breast Cancer Susceptibility Locus at 6q25.1. PLoS Genetics. 7(4). e1001382–e1001382. 43 indexed citations

14.

Léary, Alexandra, Suzanne Drury, Simone Detre, et al.. (2010). Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer with Acquired Endocrine Resistance. Clinical Cancer Research. 16(5). 1486–1497. 70 indexed citations

15.

Evans, Abigail, Sunil Pancholi, Ian Farmer, et al.. (2010). EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy. British Journal of Cancer. 102(8). 1235–1243. 18 indexed citations

16.

Pancholi, Sunil, Caroline Hilmi, Susana Banerjee, et al.. (2008). ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Endocrine Related Cancer. 15(4). 985–1002. 70 indexed citations

17.

Martin, Lesley‐Ann, Julia E. Head, Sunil Pancholi, et al.. (2007). The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo. Molecular Cancer Therapeutics. 6(9). 2458–2467. 37 indexed citations

18.

Johnston, Stephen, Julia E. Head, Sunil Pancholi, et al.. (2003). Integration of Signal Transduction Inhibitors with Endocrine Therapy. Clinical Cancer Research. 9(1). 3 indexed citations

19.

Pancholi, Sunil, Andrew B. Tullo, Asud Khaliq, David Foreman, & Mike Boulton. (1998). The effects of growth factors and conditioned media on the proliferation of human corneal epithelial cells and keratocytes. Graefe s Archive for Clinical and Experimental Ophthalmology. 236(1). 1–8. 61 indexed citations

20.

Foreman, David, Sunil Pancholi, John Jarvis-Evans, David McLeod, & M. Boulton. (1996). A Simple Organ Culture Model for Assessing the Effects of Growth Factors on Corneal Re-epithelialization. Experimental Eye Research. 62(5). 555–564. 86 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact